Lonza gains experienced scientific adviser

Company: Lonza

Professor Jonathan Knowles has joined Lonza Group in Switzerland as a part-time scientific adviser.

Professor Jonathan Knowles has joined Lonza Group in Switzerland as a part-time scientific adviser. In this role Knowles will be mainly supporting the LIFT (Lonza Innovation for Future Technologies) initiative, which aims to deliver long-term technology breakthroughs and new business platforms across all Lonza divisions. Knowles is a former member of the Roche executive committee and head of group research.

You may also like

Manufacturing

Lonza's Synaffix and BigHat Biosciences team up to develop ADC pipeline programme

Synaffix's clinical-stage ADC platform technology will allow BigHat to expand and progress its ADC pipeline for oncological indications
Research & Development

AI-enabled route scouting: a faster and better way to successful synthesis

Despite the growing focus on biologics research, small molecules still make up the lion’s share of the medicines taken by patients every year
Manufacturing

Lonza opens capsule drug development-focused site at its Colmar facility

The new addition to the French site will allow customers access to experts and technologies ideal for capsule formulation and development
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Research & Development

Overcome challenges and secure successful technology transfers of complex biological products in sterile manufacturing

The biopharmaceutical industry has seen many challenges in the last few years, spawned not just by a global pandemic but also the industry-wide disruption of operational and supply chain strategies that emerged in its aftermath...
Research & Development

Lonza launches GS Effex cell line to develop therapeutic antibodies with increased potency

The new cell line is designed to help overcome challenges in immunotherapy research and development related to the need for antibody therapeutics to have increased potency
Research & Development

Accelerating early stage small molecule drug development

Although drug discovery and development is a complex process, there are many ways that improvements can be made. Three of the issues facing drug developers — poor solubility, predicting pharmacokinetics and synthetic route selection — can all be addressed in advance to make the whole process run more effectively
Subscribe now